BBAAY
Alibaba Group Holding Ltd
No data for this timeframe.
Vol
SEC Reports5
Recent Activity
May 20, 2026
SEC
Alibaba filed its annual 20-F for FY2026 (year ended March 31, 2026), reporting full-year revenue of RMB1,023.7B (+2.7%
20-F — Impact 7/10
May 13, 2026
SEC
Alibaba reported March quarter FY2026 revenue of RMB243.4B (+3% YoY, +11% like-for-like), but operating income swung to
6-K — Impact 7/10
Apr 27, 2026
SEC
Alibaba received HKEx approval to proceed with the spin-off of its Jiaxing Park logistics asset via an infrastructure RE
6-K — Impact 3/10
Analyst Ratings
13Strong Buy
29Buy
4Hold
1Sell
0Strong Sell
Latest Reports
BEARISH
20-F
7/10
Alibaba filed its annual 20-F for FY2026 (year ended March 31, 2026), reporting full-year revenue of RMB1,023.7B (+2.7%
May 20, 2026
BEARISH
6-K
7/10
Alibaba reported March quarter FY2026 revenue of RMB243.4B (+3% YoY, +11% like-for-like), but operating income swung to
May 13, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 4.2/10.
BEARISH
20-F
7/10
Alibaba filed its annual 20-F for FY2026 (year ended March 31, 2026), reporting full-year revenue of
May 20, 2026
BEARISH
6-K
7/10
Alibaba reported March quarter FY2026 revenue of RMB243.4B (+3% YoY, +11% like-for-like), but operat
May 13, 2026
NEUTRAL
6-K
3/10
Alibaba received HKEx approval to proceed with the spin-off of its Jiaxing Park logistics asset via
Apr 27, 2026
NEUTRAL
6-K
2/10
Alibaba Group issued 58,084,712 new shares between March 31 and April 21, 2026, primarily through em
Apr 24, 2026
NEUTRAL
6-K
2/10
Alibaba Group filed a routine monthly return for March 2026, disclosing standard share capital and s
Apr 8, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 89% buy across 47 analysts — 13 strong buy, 29 buy, 4 hold, 1 sell, 0 strong sell. No current recommendation available.
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 13 | 29 | 4 | 1 | 0 | 89% | |
| Apr 1, 2026 | 13 | 28 | 5 | 1 | 0 | 87% | |
| Mar 1, 2026 | 15 | 26 | 6 | 1 | 0 | 85% | |
| Feb 1, 2026 | 15 | 26 | 6 | 1 | 0 | 85% | |
| Jan 1, 2026 | 15 | 27 | 5 | 1 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.